Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Matthias Muhar Clear advanced filters

  • Azacitidine (AZA) treatment is used for patients with myelodysplasias that cannot undergo bone marrow transplantation; however, AZA treatment is only partially effective. Here the authors show synergy of AZA with compounds inhibiting the chromatin regulators CBP and p300, which is mediated by the RNA-dependent functions of AZA affecting protein translation.

    • Jeannine Diesch
    • Marguerite-Marie Le Pannérer
    • Marcus Buschbeck
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-13

  • In leukemia, diverse fusion proteins involving the MLL gene can drive oncogenic activity. Here, the authors describe a dependency of MLL-leukemia cells on the methyltransferase SETD2 to maintain genomic integrity during leukemia initiation and maintenance.

    • Anna Skucha
    • Jessica Ebner
    • Florian Grebien
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-16

  • Loss-of-function (LOF) approaches are powerful experimental tools for characterizing gene functions. However, emerging discrepancies when genes are investigated using different tools or organisms has triggered debate about how such LOF results should be biologically interpreted. In this Review, experts from varied fields discuss how understanding the underlying features of each LOF approach can provide explanations for different experimental outcomes and can guide their optimal and reliable application.

    • Benjamin E. Housden
    • Matthias Muhar
    • Norbert Perrimon
    Reviews
    Nature Reviews Genetics
    Volume: 18, P: 24-40

  • BET bromodomain inhibitors are being explored as potential therapeutics in cancer; here, AML cells are shown to evade sensitivity to BET inhibition through rewiring the transcriptional regulation of BRD4 target genes such as MYC in a process that is facilitated by suppression of PRC2 and WNT signalling activation.

    • Philipp Rathert
    • Mareike Roth
    • Johannes Zuber
    Research
    Nature
    Volume: 525, P: 543-547